897 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Buy
Article Searches
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting http://www.zacks.com/stock/news/346748/big-pharma-ceos-indicate-more-ma-deals-at-jp-morgan-meeting?cid=CS-ZC-FT-346748 Jan 10, 2019 - Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
Where Will M&A Strike Next Across Biotech? https://seekingalpha.com/article/4232266-will-m-strike-next-across-biotech?source=feed_sector_healthcare Jan 09, 2019 - After a dearth of purchase transactions across the industry, M&A has returned in a big way early in 2019 to the biotech space.Both Celgene and Loxo Oncology have been bought out for healthy premiums e
Crowded Cancer Space Triggers Big M&A Deals: More in Store? http://www.zacks.com/stock/news/346265/crowded-cancer-space-triggers-big-ma-deals-more-in-store?cid=CS-ZC-FT-346265 Jan 08, 2019 - Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.
Why Innoviva Has 50% Upside https://seekingalpha.com/article/4231937-innoviva-50-percent-upside?source=feed_sector_healthcare Jan 07, 2019 - Innoviva is trading in a long-term, sustained, uptrend.The company reported strong EPS and revenue growth last quarter.Dividend reinstatement would bring back income investors.
Cramer: Drug stocks are an even better way than tech to invest in innovation https://www.cnbc.com/2019/01/07/cramer-drug-stocks-are-a-great-way-to-invest-in-innovation.html Jan 07, 2019 - Jim Cramer says leading drugmakers are innovating more than ever before and many of their stocks are worth owning.
GSK chief Walmsley not finished with business shakeup https://seekingalpha.com/news/3421141-gsk-chief-walmsley-finished-business-shakeup?source=feed_news_all Jan 07, 2019 - In an interview with CNBC's Jim Cramer, GlaxoSmithKline (GSK +0.7%) CEO Emma Walmsley says there are "tremendous opportunities" to improve operating performance, adding that the company will g
GlaxoSmithKline CEO Emma Walmsley gets 'radical' about reshaping portfolio https://www.cnbc.com/2019/01/07/glaxosmithkline-ceo-walmsley-gets-radical-about-reshaping-portfolio.html Jan 07, 2019 - After announcing two major deals last month, GlaxoSmithKline CEO Emma Walmsley is still looking for more chances to transform Britain's largest drugmaker.
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan http://www.zacks.com/stock/news/345648/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan?cid=CS-ZC-FT-345648 Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Top Research Reports for Facebook, Wells Fargo & AT&T http://www.zacks.com/research-daily/201456/top-research-reports-for-facebook-wells-fargo-att?cid=CS-ZC-FT-201456 Jan 02, 2019 - Top Research Reports for Facebook, Wells Fargo & AT&T
Novartis (NVS) Benefits From New Drugs & Key Acquisitions http://www.zacks.com/stock/news/345148/novartis-nvs-benefits-from-new-drugs-key-acquisitions?cid=CS-ZC-FT-345148 Dec 31, 2018 - Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.

Pages: 123456789...90

<<<Page 4>